Fannie Mae, Freddie Mac shares tumble after conservatorship comments
In a challenging turn for Harvard Bioscience (NASDAQ:HBIO), the company’s stock has plummeted to a 52-week low, trading at just $0.35, with a market capitalization of $15.9 million. This significant drop reflects a stark 1-year change, with the stock value decreasing by an alarming 90.58%. According to InvestingPro data, the company’s revenue declined by 16.14% over the last twelve months, while operating with a significant debt burden. Investors have watched with concern as the stock struggled to maintain its value, ultimately reaching this low point. The company, known for its scientific instruments and laboratory equipment, faces a critical period as it navigates through market pressures and seeks to regain investor confidence. Despite current challenges, InvestingPro analysis suggests the company appears undervalued, with analysts forecasting a return to profitability this year. Discover 10+ additional exclusive insights and detailed analysis in the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Harvard Bioscience reported its Q4 2024 earnings, revealing an earnings per share (EPS) of $0.06, surpassing the forecasted $0.05. Revenue also exceeded expectations, reaching $24.6 million compared to the anticipated $24.15 million. Despite these positive results, the company faced a 13% year-over-year decline in quarterly revenue and a 16% drop in full-year revenue. KeyBanc Capital Markets downgraded Harvard Bioscience from "Overweight" to "Sector Weight" due to concerns about financial stability and market exposure risks, particularly a waiver from lenders after breaching a consolidated net leverage ratio covenant. The company has until June 30, 2025, to refinance approximately $37 million in debt, adding to financial uncertainty. Meanwhile, Benchmark analysts maintained their Speculative Buy rating with a $4.50 price target, expecting the company’s Multi-Electrode Array system to drive growth. Additionally, Harvard Bioscience announced that CFO Jennifer Cote will depart after the submission of the 10-Q report, with Mark Frost stepping in as the interim CFO. These developments come amid a challenging market environment and uncertainties in academic research funding.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.